Apollo Therapeutics, a strategic partner of The Institute of Cancer Research, has raised more than $226m from investors to fund its ongoing collaboration with the ICR and other academic partners.
The funding has been provided by a consortium of investors led by healthcare investment firm Patient Square Capital – and will be used by Apollo to advance its existing programmes through clinical development and to acquire new, clinical stage programmes.
The ICR announced a new strategic collaboration with Apollo last year. The company was founded by and collaborates with Imperial College London, the University of Cambridge and UCL and also has a strategic agreement with Kings College London, as well as the ICR.
Successful Apollo programmes include the development of a new treatment for acute myeloid leukaemia, which it is developing in collaboration with Professor Holger Auner and Professor Matthew Fuchter from Imperial.
Apollo Therapeutics is advancing a pipeline of therapeutic programmes based on breakthrough discoveries. The company identifies and develops pre-clinical and clinical stage assets with strong biological hypotheses and the potential to become meaningful new treatment options.
Dr Jon Wilkinson, Director of Business and Innovation at the ICR, said:
“We’re very pleased to be working with Apollo as a strategic partner. Our relationship with them is a great example of how we are working in innovative new ways to try to commercialise our discoveries and, ultimately, deliver new treatments to patients.”